Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1208


Drugs of Tomorrow: Anti-asthmatics - Enter the mAbs


Description: In-depth profiles of late stage asthma products, an overview of interesting early phase compounds and forecasted new product sales, , The anti-asthmatic market is well served by existing therapies, such as the beta2-agonists and corticosteroids opinion leaders estimate that 95% of asthma patients can be successfully treated with these agents. Consequently, to attain commercial success, pipeline products need to offer significant advantages over currently marketed therapies, particularly with respect to convenience., , This Analysis provides:, , - evaluation of new compounds in development for asthma and their ability to satisfy the unmet needs of the market , , - identification of opportunities for companies to maximize the market potential of their developmental compounds , , - assessment of the impact of novel compounds on the market positions of anti-asthmatics currently leading the market , , - forecasted sales of the key anti-asthmatics that will be launched over the period 2002 to 2009,


Contents:
EXECUTIVE SUMMARY


Scope


Datamonitor insight into the asthma market


Key metrics


TABLE OF CONTENTS


PATIENT POTENTIAL


Definition of disease


Future trends in the prevalence of asthma


Segmentation of asthma


Diagnosis, treatment and compliance rates


Diagnosis


Treatment


Compliance rates


Unmet needs in asthma


Drug delivery


Efficacy


Side effects


Dosing regimens


Compliance


Disease awareness


R&D APPROACH


Classification of pipeline products


Corticosteroids


Leukotriene antagonists


Monoclonal antibodies


Phosphodiesterase-4 inhibitors


Definition of current ‘gold standard’


Clinical trials endpoints in asthma


Improvement in lung function


Decrease in steroid usage


Reduction in the incidence of acute exacerabtions


Others


Critique of clinical trial design in asthma


Preclinical trials


Clinical trials





ASTHMA PIPELINE OVERVIEW


Pipeline overview


Key drug delivery strategies in asthma


Inhaled drug delivery


Oral delivery


Injectables


Key licensing strategies and licensing oportunities in asthma


Pipeline analysis by class


Pipeline analysis by individual company





LATE STAGE DRUG ANALYSIS


Comparison of key compounds in asthma


Drug delivery


Efficacy


Side effects


Marketing strength


Monoclonal antibody (anti-IgE, anti-IL-4, anti-IL-5) drug profiles


Overview table for monoclonal antibodies





Xolair (omalizumab)


Mepolizumab (SB240563)


SCH55700


SB 240683 (pascolizumab)


Corticosteroids


Asmanex (mometasone furoate)


Ciclesonide (BY 9010)


Phosphodiesterase-4 inhibitors


Roflumilast (BY 217)


Phosphodiesterase-4 inhibitor (undisclosed)


Leukotriene antagonists


MLN977


Other Phase II compounds


SR-48968 (saredutant)


Inflarest (PB005)


GW328267


CpG 7279


IPL 576,092


EPI-2010


Recently discontinued late-stage development compounds


Nuvance (IL-4R)


Ariflo





INNOVATIVE EARLY-STAGE PROJECTS


Key Phase I and preclinical compounds in asthma


VLA-4 inhibitors


Phosphodiesterase-4 inhibitors


Monoclonal antibodies


Others








THE FUTURE DECODED


Methodology


Predicting initial market share


Forecasting future growth


Influencing factors


Market drivers in asthma


Forecast launches in asthma from 2002 to 2009


Key R&D product forecasts


Asmanex


Ciclesonide


Roflumilast


Xolair


Others





APPENDIX


Datamonitor's Immune Disorders and Inflammation Business Unit


Contributing experts


Table of tables


Table of figures


Bibliography


R&D research methodology


Introduction


Hypothesis formulation


Hypothesis testing


Data verification and quality control


Quantification of data reliability




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/1208

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 29/11/2009 09:59:14
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Drugs of Tomorrow: Anti-asthmatics - Enter the mAbs
Web Address:
http://www.researchandmarkets.com/reports/1208
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €4,137.00 + EUR€ 50.00 Shipping/Handling *
Electronic €5,104.00
* Shipping/Handling is only charged once per order.


Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 29/11/2009 09:59:14

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)